Paliperidone Extended Release: A Review of its Use in the Management of Schizophrenia

Drugs

Volumn 70, Issue 10, 2010, Pages 1295-1317

  Chwieduk, Claudine M ^a   Keating, Gillian M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Evaluations; Controlled release drugs; general; Paliperidone; Schizophrenia

Indexed keywords

AMISULPRIDE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZATROPINE; BENZODIAZEPINE DERIVATIVE; BIPERIDEN; CARBAMAZEPINE; CLOZAPINE; GLUCOSE; ILOPERIDONE; INSULIN; LIPID; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; QUETIAPINE; RISPERIDONE; VALPROATE SEMISODIUM; ZIPRASIDONE; ZOTEPINE; DELAYED RELEASE FORMULATION; ISOXAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ACUTE DISEASE; AGGRESSION; AGITATION; AKATHISIA; AMENORRHEA; AREA UNDER THE CURVE; BODY WEIGHT; CLINICAL TRIAL; DEPRESSION; DIABETES MELLITUS; DISEASE SEVERITY; DIZZINESS; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DYSTONIA; ERECTILE DYSFUNCTION; EXTRAPYRAMIDAL SYMPTOM; GALACTORRHEA; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSURIA; HEADACHE; HEART; HUMAN; HYPERGLYCEMIA; IMPOTENCE; INSOMNIA; INSULIN BLOOD LEVEL; LETHARGY; LIPID BLOOD LEVEL; LIPID METABOLISM; MENSTRUAL IRREGULARITY; MOTOR DYSFUNCTION; MUSCLE HYPERTONIA; PARKINSONISM; PROLACTIN BLOOD LEVEL; PSYCHOSIS; PULSE RATE; QT PROLONGATION; RECEPTOR AFFINITY; RECEPTOR BINDING; RECURRENT DISEASE; REVIEW; SCHIZOPHRENIA; SCORING SYSTEM; SEDATION; SEXUAL DEVIATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SINUS TACHYCARDIA; SLEEP DISORDER; SOMNOLENCE; SUICIDAL IDEATION; SYMPTOM; TARDIVE DYSKINESIA; TREATMENT DURATION; TREATMENT RESPONSE; TREMOR; WEIGHT GAIN; ADULT; CLINICAL TRIAL (TOPIC); DELAYED RELEASE FORMULATION; THERAPEUTIC USE;

ADULT; ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS AS TOPIC; DELAYED-ACTION PREPARATIONS; HUMANS; ISOXAZOLES; PYRIMIDINES; SCHIZOPHRENIA;

EID: 77953866406     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11204840-000000000-00000     Document Type: Review

References (57)

1. National Institute for Health and Clinical Excellence. Schi-zophrenia: core interventions in the treatment and management of schizophrenia in adults in primary and secondary care (updated edition). National clinical guideline number 82 [online]. Available from URL: http://www.nice.org.uk/nicemedia/live/ 11786/43607/43607.pdf [Accessed 2010 Jun 8]
2. Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004 Feb; 161 (2 Suppl.): 1-56
3. Masand PS, Roca M, Turner MS, et al. Partial adherence to antipsychotic medication impacts the course of illness in patients with schizophrenia: a review. Prim Care Companion J Clin Psychiatry 2009; 11 (4): 147-154
4. Marchese G, Pittau B, Casu G, et al. A comparison of con-tinuous subcutaneous paliperidone infusion and repeated subcutaneous injection of risperidone free-base in rats. Eur Psych 2010; 25 (2): 92-100
5. Hoy SM, Scott LJ, Keating GM. Intramuscular paliper-idone palmitate. CNS Drugs 2010; 24 (2): 92-100
6. Ortho-McNeil-Janssen Pharmaceuticals. Invega® (paliper-idone) extended-release tablets: US prescribing information [online]. Available from URL: http://www.invega.com/invega/shared/pi/invega.pdf#zoom=100 [Accessed 2010 May 24]
7. European Medicines Agency. Invega (paliperidone prolonged-release tablets): summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu/humandocs/Humans/EPAR/invega/invega.htm [Accessed 2009 Nov 30]
8. Yang LP, Plosker GL. Paliperidone extended release. CNS Drugs 2007; 21 (5): 417-25; discussion 426-427
9. Karlsson P, Dencker E, Nyberg S, et al. Pharmacokinetics and dopamine D2 and serotonin 5-HT2A receptor occupancy of paliperidone in healthy subjects: two open-label, single-dose studies [abstract no. PIII-57]. Clin Pharmacol Ther 2006 Feb; 79 (2): P74
10. Arakawa R, Ito H, Takano A, et al. Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia. Psychopharmacology (Berl) 2008 Apr; 197 (2): 229-235
11. Knegtering R, Baselmans P, Castelein S, et al. Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels. Am J Psychiatry 2005 May; 162 (5): 1010-1012
12. Berwaerts J, Cleton A, Rossenu S, et al. A comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patients with schizophrenia. J Psychopharmacol. Epub 2009 Oct 13
13. Kane J, Canas F, Kramer M, et al. Treatment of schizo-phrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res 2007 Feb; 90 (1): 147-161
14. Davidson M, Emsley R, Kramer M, et al. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophr Res 2007 Jul; 93 (1-3): 117-130 (Pubitemid 46817944)
15. Marder SR, Kramer M, Ford L, et al. Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. Biol Psychiatry 2007 Dec 15; 62 (12): 1363-1370
16. Tzimos A, Samokhvalov V, Kramer M, et al. Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extension. Am J Geriatr Psychiatry 2008 Jan; 16 (1): 31-43
17. Canuso CM, Dirks B, Carothers J, et al. Randomized, double-blind, placebo-controlled study of paliperidone extended-release and quetiapine in inpatients with recently exacerbated schizophrenia. Am J Psychiatry 2009 Jun; 166 (6): 691-701
18. Meltzer HY, Bobo WV, Nuamah IF, et al. Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies. J Clin Psychiatry 2008 May; 69 (5): 817-829
19. Kramer M, Eerdekens M, Lane R, et al. Metabolic out-comes, in terms of weight, glucose and lipid profiles, in patients with schizophrenia treated with paliperidone extended-release tablets for 52 weeks [abstract]. 160th Annual Meeting of the American Psychiatric Association; 2007 May 19-24; San Diego (CA), 213-214
20. Eerdekens M, Kramer M, Cleton A, et al. Paliperidone ex-tended-release and quetiapine therapy in schizophrenia or schizoaffective disorder: evaluation of QT/QTc intervals. Eur Neuropsychopharmacol 2007 Oct; 17 Suppl. 4: 469
21. Schreiner A, Korcsog P, Niehaus D, et al. A prospective randomized controlled trial of paliperidone ER versus oral olanzapine in patients with schizophrenia [abstract no. SCH-3020]. 15th Biennial Winter Workshop on Psychoses; 2009 Nov 15-18; Barcelona
22. Luthringer R, Staner L, Noel N, et al. A double-blind, pla-cebo-controlled, randomized study evaluating the effect of paliperidone extended-release tablets on sleep architecture in patients with schizophrenia. Int Clin Psychopharmacol 2007 Sep; 22 (5): 299-308
23. European Medicines Agency. Invega (paliperidone prolonged-release tablets): scientific discussion [online]. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/invega/H-746-en6.pdf [Accessed 2009 Nov 30]
24. 2 receptor occupancy for long-acting injectable risperidone. Am J Psychiatry 2006 Mar; 163 (3): 396-401
25. Kapur S, Zipursky R, Jones C, et al. Relationship between dopamine D2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 2000; 157 (4): 514-520
26. Kapur S, Zipursky RB, Remington G. Clinical and theore-tical implications of 5-HT2 and D2 receptor occupancy or clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 1999 Feb; 156 (2): 286-293
27. Emsley R, Berwaerts J, Eerdekens M, et al. Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies. Int Clin Psychopharmacol 2008 Nov; 23 (6): 343-356
28. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994
29. Vermeir M, Boom S, Naessens I, et al. Absorption, metabolism and excretion of a single oral dose of (14)C-paliper-idone 1 mg in healthy subjects [abstract no. P.8.097]. Eur Neuropsychopharmacol 2005 Oct; 15 Suppl. 3: 648-649. Plus poster presented at the 18th European College of Neuropsychopharmacology Congress; 2005 Oct 22-26; Amsterdam
30. Cleton A, Rossenu S, Vermeulen A, et al. A pharmaco-kinetic model to document the interconversion between paliperidone's enantiomers [abstract no. PII-72]. Clin Pharmacol Ther 2006 Feb 1; 79 (2): 55
31. Rossenu S, Crauwels H, Cleton A, et al. Evaluation of the pharmacokinetics of several formulations of paliperidone. AAPS J 2006; 8 Suppl. 2: 1042
32. Cirincione BB, Redman ML, Fiedler-Kelly J, et al. Popula-tion pharmacokinetics of paliperidone ER in healthy and schizophrenia patients. Clin Pharmacol Ther 2007 Mar; 81 Suppl. 1: 19
33. Boom S, Talluri K, Janssens L, et al. Single-and multiple-dose pharmacokinetics and dose proportionality of the psychotropic agent paliperidone extended release. J Clin Pharmacol 2009 Nov; 49 (11): 1318-1330
34. Berwaerts J, Cleton A, Herben V, et al. The effects of par-oxetine on the pharmacokinetics of paliperidone extended-release tablets. Pharmacopsychiatry 2009 Jul; 42 (4): 158-163
35. Thyssen A, Cleton A, Talluri K, et al. No pharmacokinetic interaction between paliperidone extended-release tablets and trimethoprim in healthy subjects. Hum Psycho-pharmacol 2009; 24: 532-539
36. Kramer M, Simpson G, Maciulis V, et al. Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psycho-pharmacol 2007 Feb; 27 (1): 6-14
37. Canuso C, Carothers J, Dirks B, et al. A double-blind, pla-cebo-controlled trial of paliperidone ER and quetiapine in patients with a recent acute exacerbation of schizophrenia [abstract]. 161st Annual Meeting of the American Psychiatric Association; 2008 May 3-8; Washington, DC, 166
38. Schreiner A, Tessier C, Hoeben D, et al. A prospective ran-domized controlled trial of paliperidone ER versus oral olanzapine in patients with schizophrenia [abstract]. 18th European Congress of Psychiatry; 2010 Feb 27-Mar 2; Munich
39. Schreiner A, Hoeben D, Lahaye M, et al. A flexible-dose study of paliperidone ER in non-acute patients with schizophrenia previously unsuccessfully treated with other oral antipsychotics [abstract]. 18th European Congress of Psychiatry; 2010 Feb 27-Mar 2; Munich
40. Schreiner A, HoebenD, Lahaye M, et al. Patient functioning with flexible doses of paliperidone ER: a 6-month prospective study [abstract]. 18th European Congress of Psychiatry; 2010 Feb 27-Mar 2; Munich
41. Schreiner A, Hoeben D, Lahaye M, et al. A flexible-dose study of paliperidone ER in non-acute patients with schizophrenia previously unsuccessfully treated with oral ris-peridone [abstract]. 18th European Congress of Psychiatry; 2010 Feb 27-Mar 2; Munich
42. Howland RH. Paliperidone extended-release tablets: a new atypical antipsychotic. J Psychosoc Nurs Ment Health Serv 2007 May; 45 (5): 15-18
43. Salimi K, Jarskog LF, Leiberman JA. Antipsychotic drugs for first-episode schizophrenia. CNS Drugs 2009; 23 (10): 837-855
44. Mortimer A. How do we choose between atypical antipsy-chotics? The advantages of amisulpride. Int J Neuropsy-chopharmacol 2004; 7 Suppl. 1: S21-5
45. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychot-ics: a systematic review of 1-year studies. Am J Psychiatry 2004 Mar; 161 (3): 414-425
46. Kapur S, Seeman P. Does fast dissociation from the dop-amine D2 receptor explain the action of atypical antipsy-chotics? A new hypothesis. Am J Psychiatry 2001 Mar; 158 (3): 360-369
47. Falkai P. Limitations of current therapies: why do patients switch therapies? Eur Neuropsychopharmacol 2008; 18 Suppl.: S135-9
48. American Diabetes Association. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004 Feb; 27 (2): 596-601
49. Jones A. What are the nursing implications when using pa-liperidone prolonged release for people with schizophrenia. J Psychiatr Ment Health Nurs 2008 Dec; 15 (10): 792-799
50. Hough D, Nuamah IF, Lim P, et al. Independent effect of paliperidone extended release on social functioning beyond its effect on positive and negative symptoms of schizophrenia: a mediation analysis [letter]. J Clin Psycho-pharmacol 2009 Oct; 29 (5): 496-497
51. Schreiner A, Badescu GM, Jukic V, et al. Safety, tolerability and treatment response of flexible doses of paliperidone ER in acutely exacerbated patients with schizophrenia [abstract]. 9th World Congress of the World Federation of Societies of Biological Psychiatry; 2009 Jun 28-Jul 2; Paris
52. Kantrowitz J, Citrome L. Paliperidone: the evidence of its therapeutic value in schizophrenia. Core Evidence 2008; 2 (4): 261-271
53. Nussbaum A, Stroup TS. Oral paliperidone for schizo-phrenia. Cochrane Database Syst Rev 2009; (2): CD006369
54. US National Institutes of Health. A double-blind, placebo-controlled study of the safety and efficacy of paliperidone extended release (ER) in the treatment of schizophrenia in adolescent patients [online]. Available from URL: http://www.clinicaltrials.gov/ct2/show/record/NCT00518323 [Accessed 2010 May 3]
55. Geitona M, Kousoulakou H, Ollandezos M, et al. Costs and effects of paliperidone extended release compared with alternative oral antipsychotic agents in patients with schizophrenia in Greece: a cost effectiveness study. Ann Gen Psychiatry 2008; 7: 16
56. Edwards NC, Pesa J, Meletiche DM, et al. One-year clinical and economic consequences of oral typical antipsychotics in the treatment of schizophrenia. Curr Med Res Opin 2008 Dec; 24 (12): 3341-3355
57. Berto P, Negrini C, Ferrannini L. Analisi costo-efficacia di paliperidone ER nel trattamento delle ricadute della schi-zofrenia, nella prospettiva del Sistema Sanitario Nazionale italiano. Farmeconomia e Percorsi Terapeutici 2008; 9 (2): 95-108